Angiotensin-Receptor Blocker, Angiotensin-Converting Enzyme Inhibitor, and Risks of Atrial Fibrillation

Angiotensin-Receptor Blocker, Angiotensin-Converting Enzyme Inhibitor, and Risks of Atrial Fibrillation

Both angiotensin-receptor blockers (ARB) and angiotensin-converting enzyme inhibitors (ACEI) have protective effects against atrial fibrillation (AF). The differences between ARB and ACEI in their effects on the primary prevention of AF remain unclear. This study compared ARB and ACEI in combined antihypertensive medications for reducing the risk of AF in patients with hypertension, and determi...

Angiotensin Converting Enzyme in Sarcoidosis

Effects of Angiotensin Converting Enzyme Inhibitor Versus Angiotensin II Receptor Blocker

Background. The degree of cardiac hypertrophy is not only load dependent: Among other factors, the renin-angiotensin system may play a role in the regulation of cardiac myocyte growth. Methods and Results. To evaluate the role of the renin-angiotensin system in volume overload-induced cardiac hypertrophy, we assessed 1) the time course of changes in cardiac hemodynamics, cardiac anatomy, and pl...

Review: Angiotensin II receptor blocker plus angiotensin-converting enzyme inhibitor increases risk for adverse effects.

M e t h o d s Data sources: MEDLINE and EMBASE/ Excerpta Medica (to December 2006), Cochrane Library, National Institutes of Health Clinical Trials and US Food and Drug Administration Web sites, and reference lists. Study selection and assessment: Randomized controlled trials (RCTs) with ≥ 500 patients that compared the combination of ARB and ACE-I with standard therapy that included ACE-I for ...

Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis.

OBJECTIVES This study was designed to identify all randomized clinical trial data evaluating angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for the prevention of atrial fibrillation (AF), to estimate the magnitude of this effect and to identify patient subgroups most likely to benefit. BACKGROUND Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin recep...